Biodistribution Of RNA Viral Vector Vaccine I Pharmaron CRO

Human respiratory syncytial virus (RSV) remains a significant cause of severe respiratory disease, particularly in vulnerable populations such as children and the elderly. With limited effective vaccines available, viral vector vaccines derived from RNA viruses offer promising safety and immunogenicity advantages.

This study describes the method validation of a one-step RT-qPCR to investigate the biodistribution of RNA virus vaccine against RSV in Sprague-Dawley rats after nasal administration. Tissues from key organ systems and blood were collected for analysis. RNA extraction was performed using the Kingfisher Apex, followed by RT-qPCR analysis on the QuantStudio system. Method qualification confirmed robust accuracy, precision, and stability.

Download our poster to see the detailed results of the One-Step RT-qPCR method validation.

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.